Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence. Suzuki H, Akamatsu S, Shiota M, Kakiuchi H, et al. Int J Urol 2024 Dec 9. doi: 10.1111/iju.15647.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Suzuki H, Akamatsu S, Shiota M, Kakiuchi H, et al. Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence. Int J Urol 2024 Dec 9. doi: 10.1111/iju.15647.
PMID: 39651632